Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03770468

Enrollment

599

Registered

2018-12-10

Start date

2015-07-05

Completion date

2023-08-18

Last updated

2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are: * Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1) * Identification of molecular tumor characteristics in long-term survivors (Focus 2) * Assessment of therapy-related parameters, including neuro-toxicity (Focus 3) * Immunological studies (Focus 4)

Interventions

PROCEDUREBlood drawl

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years at diagnosis * Histopathological diagnosis of glioblastoma (reference histology available) and * Survival \>5 years from diagnosis * Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally. * Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients

Exclusion criteria

* Not applicable

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival	1 year from last patient in	—
Molecular profiling on FFPE samples	1 year from last patient in	Profiling for cytosine-phosphate-guanosine (CpG) methylation patterns using the Illumina 850k bead array platform
Molecular profiling on frozen samples	1 year from last patient in	Samples will be subjected to whole exome sequencing
Proteome profiling	1 year from last patient in	Tumor cells will be microdissected from frozen sections and prepared for high-resolution mass spectrometry

Countries

Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026